Back to Screener

ANAPTYSBIO, INC (ANABV)

NASDAQ
Data as of Sep 30, 2025 (TTM)

Investment Snapshot

  • Piotroski F-Score 5/9 — moderate financial health
  • Loss-making — negative ROE of -257.2%
  • Revenue growing at 157% annually

ANAPTYSBIO, INC (ANABV) is a publicly traded company, listed on the NASDAQ . Key value metrics: Piotroski F-Score 5 out of 9 (moderate financial health) .

Value Score

Key Metrics

P/E Ratio
EPS
$-3.33
Div. Yield
PEG Ratio
P/S Ratio
EV/EBITDA
ROE
ROA
Gross Margin
Op. Margin
Net Margin
Debt/Equity
Current Ratio
Data sourced from SEC EDGAR and Polygon.io. Methodology.

ANAPTYSBIO, INC — Fundamental Analysis Summary

On financial health, ANABV shows a moderate Piotroski F-Score of 5/9, and negative return on equity of -257.2%.

StockPik's composite Value Score for ANABV is 47/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.

ANABV shows revenue growing at 157% year-over-year, with earnings growing at 91%.

How is the Value Score calculated?
Read our full methodology →
What is the Piotroski F-Score?
The 9-point financial health score explained, with worked examples →
Previous
ANAB
Next
ANDE